Загрузка...
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
BACKGROUND: Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs failure-free survival for those without. To date the...
Сохранить в:
| Опубликовано в: : | Eur Urol Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier B.V
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6692495/ https://ncbi.nlm.nih.gov/pubmed/31158087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euo.2018.06.004 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|